RESUMEN
This case report presents a 7-month-old male who was admitted to the emergency room with red-colored stools, initially raising concerns for serious gastrointestinal issues. The child, who had a history of milk protein allergy and eczema, had recently been prescribed cefdinir for an ear infection and was also consuming a hydrolyzed formula containing iron. Despite initial findings of elevated white blood cell count, mild anemia, and hyperkalemia, a stool heme-occult test was negative. The negative heme-occult lead to the consideration of cefdinir-induced stool discoloration as a possible diagnosis, a benign side effect that occurs in the presence of iron supplementation. Following the discontinuation of cefdinir, the patient's symptoms resolved completely on follow up with his pediatrician. A rare occurrence, cefdinir-induced red stool discoloration must be considered in cases of benign appearing infants with "bloody" stools.
RESUMEN
Valproic acid (VPA) is utilized in the management of a variety of seizure and mood disorders. A rare side effect of this medication is dose-dependent thrombocytopenia. In this case, we report a patient with a treatment-resistant epilepsy GABRB3 genetic variant phenotype who was admitted for sepsis and found to have significant thrombocytopenia with clinical manifestations of epistaxis and easy bruising, which was found to be due to VPA use rather than secondary to other clinical pathologies. The patient's clinical condition improved with supportive treatment including fluid rehydration. Platelet counts normalized after a transfusion and holding of her valproate. She experienced breakthrough seizures despite the initiation of diazepam. The decision was made to restart VPA per Neurology consult recommendations for better seizure control. She had no breakthrough seizures reported after restarting VPA in the hospital. This case highlights the importance of monitoring antiseizure medication side effects, especially in populations at higher risk due to treatment resistance.
RESUMEN
This study examines the safety and efficacy of using peak anti-Xa levels to achieve prophylactic enoxaparin (Lovenox, Sanofi-Aventis) levels in patients who underwent hepatic surgery. Prospectively enrolled patients undergoing major and minor hepatic procedures received postoperative enoxaparin dosing. The enoxaparin dose was adjusted to attain a peak anti-Xa level ≥ 0.20 U/ml. This group was compared to a historical cohort of patients who underwent similar procedures and received standard postoperative VTE chemoprophylaxis dosing. Inpatient postoperative VTE rates were higher in the control group when compared to the experimental group (0 patients [0.00%] vs 4 patients [8.16%]; P = .035). There was no statistically significant difference in number of postoperative blood transfusions, discharge hemoglobin, or in-hospital bleeding events. Adjusting enoxaparin dosing to achieve prophylactic peak anti-Xa levels of ≥0.20 IU/ml was associated with a reduced incidence of symptomatic inpatient postoperative VTE in patients who underwent hepatic surgery without increasing postoperative bleeding events.